Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use. Postmenopausal women using hormone therapy had ...
Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...
Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...
CBT is an evidence-based, nonhormonal option endorsed by the National Institutes of Health and The Menopause Society for ...
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while ...
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC ...
For primary care physicians, the question is increasingly whether continuous glucose data could answer a clinically useful ...
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...
Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...
Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results